In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Etiologics Ltd.

Division of Charles River Laboratories International Inc.
www.mvfund.com/etiologics

Latest From Etiologics Ltd.

GW/Bayer: Sharing Value

In its late-stage licensing deal with GW Pharmaceuticals for Sativex, Bayer accepted UK-only rights, and will share the product's value equally with GW. This unusual agreement largely reflects the particular nature of the product. But it also shows that, at least in some situations, biotechs can still partner out their jewels without giving away too much value.
BioPharmaceutical Europe

Recent Dealmaking (7/2003)

Summarizing the month in European dealmaking.
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Charles River Laboratories International Inc.
  • Senior Management
  • Christopher Ashton, PhD, CEO
    David Campbell, CSO
  • Contact Info
  • Etiologics Ltd.
    Phone: (44) 1235 841 000
    c/o Medical Research Council, Mammalian
    Genetics Unit
    Harwell, OX11 0RD
    UK
UsernamePublicRestriction

Register